{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:50:05Z","timestamp":1761562205582,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.carrev.2017.06.009","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T15:02:38Z","timestamp":1498143758000},"page":"112-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"PB","title":["Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: A United States-based case series"],"prefix":"10.1016","volume":"19","author":[{"given":"Charles I.","family":"Wilmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2017.06.009_bb0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2005.09.080","article-title":"Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb\/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention","volume":"97","author":"Danzi","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0010","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.ahj.2007.05.007","article-title":"Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study","volume":"154","author":"Mardikar","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2017.06.009_bb0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2004.02.059","article-title":"Ability of anti-glycoprotein IIb\/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions","volume":"44","author":"Goto","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0020","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.103.21.2572","article-title":"Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study","volume":"103","author":"Steinhubl","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2017.06.009_bb0025","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.jacc.2009.11.091","article-title":"Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome","volume":"55","author":"ten Berg","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0030","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/j.1538-7836.2009.03573.x","article-title":"Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction","volume":"7","author":"Heestermans","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.carrev.2017.06.009_bb0035","first-page":"e344","article-title":"2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: a Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2017.06.009_bb0040","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.carrev.2016.09.011","article-title":"Comparison of heparin, bivalirudin, and different glycoprotein IIb\/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: a network meta-analysis","volume":"17","author":"Lipinski","year":"2016","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2017.06.009_bb0045","first-page":"53","article-title":"High-dose tirofiban administered as bolus-only during percutaneous coronary intervention","volume":"20","author":"Marmur","year":"2008","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0050","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacc.2008.09.060","article-title":"Abbreviated infusion of eptifibatide after successful coronary intervention. The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial","volume":"53","author":"Fung","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ihj.2012.07.022","article-title":"Safety and efficacy of bivalirudin with glycoprotein IIb\/IIIa for high-risk percutaneous coronary intervention","volume":"64","author":"Deshpande","year":"2012","journal-title":"Indian Heart J"},{"key":"10.1016\/j.carrev.2017.06.009_bb0060","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ahj.2014.03.011","article-title":"Comparison of double (360mg) ticagrelor loading dose with standard (60mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study","volume":"167","author":"Parodi","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2017.06.009_bb0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","volume":"5","author":"Valgimigli","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2017.06.009_bb0075","doi-asserted-by":"crossref","first-page":"e001593","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593","article-title":"Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"8","author":"Parodi","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2017.06.009_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11239-012-0814-7","article-title":"Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability","volume":"36","author":"Speich","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.carrev.2017.06.009_bb0085","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/CIRCULATIONAHA.109.882746","volume":"121","author":"Deibele","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2017.06.009_bb0090","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00005344-200304000-00011","article-title":"Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates","volume":"41","author":"Moser","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"year":"2015","series-title":"Aggrastat [package insert]","key":"10.1016\/j.carrev.2017.06.009_bb0095"},{"year":"2014","series-title":"Integrilin [package insert]","key":"10.1016\/j.carrev.2017.06.009_bb0100"},{"year":"2013","series-title":"ReoPro [package insert]","key":"10.1016\/j.carrev.2017.06.009_bb0105"},{"key":"10.1016\/j.carrev.2017.06.009_bb0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/ehp376","article-title":"Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials","volume":"31","author":"Valgimigli","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2017.06.009_bb0115","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1253\/circj.CJ-08-0357","article-title":"Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome","volume":"72","author":"Wu","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.carrev.2017.06.009_bb0120","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5152\/akd.2010.093","article-title":"Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention","volume":"10","author":"Erdim","year":"2010","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1016\/j.carrev.2017.06.009_bb0125","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3760\/cma.j.issn.0366-6999.20130466","article-title":"Randomized comparison of intracoronary tirofiban versus urokinase as an adjunct to primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: results of the ICTUS-AMI trial","volume":"126","author":"Zhu","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.carrev.2017.06.009_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijcard.2011.08.082","article-title":"Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study","volume":"165","author":"Zhu","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0135","first-page":"3690","article-title":"Safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction undergoing percutaneous coronary intervention","volume":"18","author":"Wang","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.carrev.2017.06.009_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12013-014-0173-4","article-title":"Effects of tirofiban on platelet activation and endothelial function in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"71","author":"Wang","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.carrev.2017.06.009_bb0145","first-page":"59","article-title":"Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"79","author":"Kirma","year":"2012","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2017.06.009_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11239-012-0685-y","article-title":"Intracoronary versus intravenous high-dose bolus plus maintenance administration of tirofiban in patients undergoing primary percutaneous coronary intervention for acute ST elevation myocardial infarction","volume":"34","author":"Candemir","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.carrev.2017.06.009_bb0155","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/0003319714545780","article-title":"Acute effects of intracoronary tirofiban on no-reflow phenomena in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention","volume":"66","author":"Akpek","year":"2015","journal-title":"Angiology"},{"key":"10.1016\/j.carrev.2017.06.009_bb0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2016.01.204","article-title":"Intracoronary injection of tirofiban prevents microcirculation dysfunction during delayed percutaneous coronary intervention in patients with acute myocardial infarction","volume":"208","author":"Sun","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0165","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.hlc.2015.04.161","article-title":"Effect of intracoronary plus low-dose intravenous tirofiban in elderly patients with acute myocardial infarction","volume":"24","author":"Zhao","year":"2015","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.carrev.2017.06.009_bb0170","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.amjcard.2011.06.039","article-title":"Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome","volume":"108","author":"Friedland","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0175","doi-asserted-by":"crossref","first-page":"e0129718","DOI":"10.1371\/journal.pone.0129718","article-title":"Efficacy and safety of intracoronary versus intravenous administration of tirofiban during percutaneous coronary intervention for acute coronary syndrome: a meta-analysis of randomized controlled trials","volume":"10","author":"Tang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.carrev.2017.06.009_bb0180","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0002-9149(02)02892-8","article-title":"Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban","volume":"90","author":"Schneider","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0185","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0002-9149(02)03163-6","article-title":"Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban","volume":"91","author":"Schneider","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2017.06.009_bb0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)85010-1","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"Topol","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2017.06.009_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9343(02)01145-2","article-title":"Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization","volume":"113","author":"Topol","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.carrev.2017.06.009_bb0200","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jcin.2015.04.031","article-title":"Impact of glycoprotein IIb\/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the National Cardiovascular Data Registry","volume":"8","author":"Safley","year":"2015","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838917301999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838917301999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:13:03Z","timestamp":1761559983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838917301999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1553838917301999"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2017.06.009","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: A United States-based case series","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2017.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}